
|Videos|December 19, 2022
2022 SUO Annual Meeting recap: Use of doublet therapy in metastatic prostate cancer varies by location
Author(s)Urology Times staff
“This study highlights how treatment remains influenced by where you live,” Diana Magee, MD, MPH, MSc.
Advertisement
In this video, Diana Magee, MD, MPH, MSc, summarizes the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












